COMPOSITION FOR DRUG DELIVERY COMPRISING NICOTINE OR A DERIVATIVE THEREOF AND STARCH MICROSPHERES AND METHOD FOR THE MANUFACTURING THEREOF

Abstract: A powdery pharmaceutical composition comprising nicotine or a derivative thereof and starch microspheres. The starch microspheres are preferably degradable epichlorhydrin cross-linked starch microspheres. The average diameter of the microspheres is from around 1 mu m to around 200 mu m, preferably around 45 mu m. The invention also encompasses a method for manufacturing a powdery pharmaceutical composition comprising nicotine and starch microspheres. The invention further comprises a method of diminishing the desire of a subject to use tobacco which comprises the step of administering to the subject the above powdery pharmaceutical composition.

Description: Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the manufacturing thereof Field of invention The present invention concerns a composition for drug delivery and a method for the manufacturing thereof. Specifically the invention concerns a composition in which a drug is bound to starch microspheres. The composition according to the invention is of particular interest for nasal delivery. The composition is primarily intended as an aid in nicotine replacement therapy. Objectives of the invention A primary objective of the invention is to provide for a new and inventive pharmaceutical composition for nasal, oral, buccal or pulmonary administration of nicotine. The objective is achieved with a powdery composition comprising nicotine incorporated in degradable starch microspheres. A further objective of the invention is to provide for a method of incorporating nicotine into starch microspheres. A still further objective of the invention is to provide for a method for diminishing the desire of a person to use tobacco which comprises administering to that person a composition comprising nicotine incorporated into degradable starch microspheres. Background In the U.S. Surgeon General ' s 1979 report on Smoking and Health, it was estimated that in the U.S. alone about 350,000 deaths are caused each year by diseases related to cigarette smoking. In fact, excessive smoking is now recognized as one of the major health problems throughout the world. HEET The most advantageous thing a heavy smoker can do is, therefore, to reduce or preferably even stop smoking completely. Experience shows, however, that most smokers find this extremely difficult. It is generally accepted that this difficulty results from the fact that heavy smokers are dependent on nicotine, which is considered to be one of the risk factors in tobacco smoke. The most important risk factors, however, are substances which are formed during the combustion of tobacco, such as carbon monoxide, tar products, aldehydes, and hydrocyanic acid. One way to reduce smoking would, of course, be to provide nicotine in a form or manner other than by smoking. There are available tobacco products which can be used for this purpose, such as chewing tobacco and snuff, which latter material can be administered both via nasal and oral routes. Tobacco products of this type are, however, not without harmful effects, such as cancer, and are not well accepted socially. One already existing product, which fulfils the above-mentioned objective of providing nicotine in a less harmful and more socially-acceptable manner, is a nicotine chewing gum. Nicotine-containing chewing gums are not new. U.S. Pat. No 865,026 and 940,521 are representative of ancient efforts along these lines. More recently, however, U.S. Pat. No 3,877,468, 3,901 ,248 and 3,845,217 have appeared, and the products of the latter of these three patents are now being marketed on an international scale. These products combine a nicotine-containing cation exchange resin complex in gum base, preferably together with a buffering agent which maintains the pH of the saliva above its normal physiological pH. It seems particularly difficult to find other smoking substitutes equivalent to or as effective as the chewing gum substitutes just mentioned, and the aerosol compositions of the Gildermeister or Smith British Pat. Nos. 1 ,528,391 or 2,030,862, adapted to be sprayed into the mouth of the user, are hardly an answer to the problem and in actuality appear to be merely a particular extension of a suggestion made as early as 1967 (A. Herxheimer et al, Lancet 1967, II 754-5). Unilever in German Offenlegungsschrift No 2,313,996, published Oct. 10, 1974, describes certain water-soluble readily-absorbed snuff powders and a process for their manufacture, but these involve only extracts of tobacco aroma combined with solid water-soluble adsorbents. Such snuff substitutes are supposedly less prone to discolour teeth, fingers, and so on, but contribute nothing as far as the problem presently under consideration and certainly suggest no socially-acceptable solution with respect thereto. In recent years transdermal administration of nicotine by way of patches has been suggested, i.a. by Miranda et al in US 4,915,950. Ingestion of nicotine vapors orally has been disclosed by Turner et al in US 5,167,242. The authors suggest a nicotine-impermeable container and a nicotine inhaling device in which the container is placed. The inhaling device has outer resemblancies with a cigarette and is supposed to be "smoked" like a cigarette although no pyrolysis takes place. One socially- and toxicologically-acceptable way of administering nicotine is by way of the administration directly into the nasal cavity. A smoking substitute for application directly into the nose was disclosed by Fernό, Helgertz and Ohlsson in US 4,579,858. This substitute is in the form of an aqueous nicotine solution characterized by defined ranges for nicotine concentration, pH value and viscosity. Although said aqueous solution provides for a useful way of nasal administration of nicotine it has certain drawbacks, such as irritative effects on the nasal mucosa. Even if the bioavailability of the above aqueous nicotine is fairly high it would be of advantage if the bioavailability for nasally administered nicotine could be increased thereby decreasing the amount of nicotine needed to be administered for arriving at a certain plasma concentration. Minute polysaccharide particles which may be used in the present invention were disclosed by Rothmann and Lindberg in US 4,124,705. The particles according to this patent are intended for intravascular administration in a suspension. Upon administration said particles block the finer blood vessels of the body. The authors disclose coadministration of the polysaccharide particles and a diagnostic agent. Anyhow Rothmann and Lindberg do neither suggest nasal administration nor the incorporation of nicotine into the particles. Administration of drugs to the nasal mucosa can be done by way of powdery pharmaceutical compositions for application to the nasal mucosa. Lisbeth Ilium discloses in WO 88/09163 a drug delivery system including a plurality of microsphere particles containing an active drug and including a surfactant material associated with each particle. The particles may be made of i.a. starch or gelatin. Suitable drugs include vaccine and polypeptides. Lisbeth Ilium discloses in WO89/03207 a drug delivery composition, for i.a. nasal administration, comprising a plurality of microspheres and active drug associated with each such microsphere. The drugs have a maximum molecular weight of 6.000 and the microspheres may be of starch, gelatin or albumin. Suitable drugs include insulin and antigenic vaccine ingredients. Nicotine is not suggested neither in WO 88/09163 nor in WO89/03207. TEIJIN LIMITED discloses in EP 122 036 a powdery pharmaceutical composition for nasal administration comprising a water-absorbing and water-insoluble base. This base might be i.a. starch. This invention is anyhow limited to the administration of a physiologically active polypeptide. There is no mentioning of nicotine in EP 122 036. Examples The invention will be illustrated by a few non-limiting examples. Materials Nicotine base was purchased from Kodak (batch No 42904). Degradable Starch Microspheres (DSM) particles were obtained from Kabi Pharmacia, Sweden. Their registration trademark is Spherex ® . Degradable Starch Microspheres (DSM) used in the present invention are characterized in the above mentioned patent US 4,124,705 in which also are disclosed methods for their manufacturing. The DSM substance consists of a polymeric matrix of cross-linked starch of complex chemical structure and, therefore, cannot be described simply by means of a conventional chemical name. The INN name is amilomer, amilomerum. The substance cannot, for the same reason as above, be meaningsfully represented by a single structural formula. The chemical structure of starch microspheres is composed of starch fragments from hydrolyzed potato starch crosslinked and substituted with glycerol ether moieties. These occur as single as well as oligomeric crosslinks of substituents with varying substructure. The molecular weight of the polymeric network of the matrix is undefined and may be assumed to be infinite. The size of the starch microspheres is characterized by a diameter distribution measured as volume distribution on swelled beads. The average diameter is 45 μm and more than 95 % of the microspheres have a diameter between 20 and 70 μm. In short the Spherex ® particles used in the present invention can be characterized as degradable epichlorhydrin cross-linked starch microspheres with a mean diameter of 45 μm when swollen and a biological degradation time (tVS) of 25 minutes when degraded in 240 lU/ml amylase solution. The Spherex ® particles used in the present invention have several functions: The particles acts as a drug carrier. When deposited in the nasal cavity, the clearance due to mucusal flow is reduced. By taking up water it is believed that the particles dehydrate the nasal epithelium thereby opening the tight junctions connecting the cells and thus increasing the paracellular uptake of the drug. Example 1 Preparation of lyophilised formulations The nicotine-Spherex ® batch used for the biological experiments according to the following Example 2 was prepared by mixing 100 mg Spherex ® particles with 850 μl 2 % nicotine solution in demineralised water corresponding to 17 mg nicotine base/100 mg Spherex ® particles. This mixture equilibrated for 1 hour at room temperature and was thereafter freeze dried to obtain a powdery formulation. The freeze dried material was sieved through a 60 μm sieve before use. Example 2 Estimation of the bioavailability of nicotine bound to Spherex ® microspheres when administered intranasally. Rat studies Male Lewis rats (Lew/Mol) purchased from Møllegaard, Denmark, were used for the studies. The animals were fed unlimited on Altromin 1324 and supplied with tap water. The rats were fasted 18-24 hours prior to experimental start. The rats weighed not less than 200 g when used for experiments. The rats were anaesthetized with Mebumal (50 mg/ml) in an initial dose of 50 mg/kg bodyweight (i.p.). If signs of reflexes were observed during the experiment, a supplementary dose (10 mg/kg) was given. The anaesthetized rats were fixated on thermostated plates maintaining a body temperature of 37°C. The trachea was cannulated using a PE 200 polyethylene tubing thus assessing free airways. The anterior part of the trachea was closed with surgical thread thus leaving nasal formulations/administrations in the anterior part of the airways. The oesophagus was closed for the same reasons. The aorta carotis was cannulated using a 24 G/ V*" indwelling cannula. Vena femoralis was similarly cannulated to secure a constant blood volume due to blood sampling. Blood samples (250 μl) were withdrawn from aorta carotis and an equal volume physiological saline was injected through vena femoralis. Lyophilized nicotine-Spherex ® microspheres prepared in accordance with Example 1 were administered by blowing the powder into one of the nostrils of the rat. The powdery formulation was deposited in a PE 90 polyethylene tubing in an amount corresponding to a dose of approx. 7 mg powdery formulation/kg BW. When administering the powder, the tubing was guided into the nostril and the content blown out by blowing 500 μl air through the tubing by use of a syringe. The amount of powder administered was calculated by weighing the tubing before and after administration. For the calculation of the bioavailability of the nicotine when administered intranasally, intravenous injections of nicotine were performed. The experimental setup was the same as described above, except for the administration of nicotine which was injected into vena femoralis (0.15 mg nicotine/kg BW from a solution of 0.3 mg nicotine/ml physiological saline). Calculation of pharmacokinetic parameters The pharmacokinetic parameters were determined using the SIPHAR/Kinetics software program from SIMED (France). Intranasal administration The plasma values from each animal were plotted in a semi-logaritmic plot whereby the number of phases could be determined visually. Two phases were observed. The data were therefore analysed assuming one compartment of distribution and two phases, an absorption and an elimination phase. The model was fitted to the data using weighed least squares algoritm with the weighing factor = 1. Intravenous administration The plasma values obtained after i.v. administration of nicotine were just like those obtained by intranasal administration analysed for the number of phases. One phase was recognized corresponding to only one elimination phase. The model was fitted to the data using weighted least squares algoritm with the weighing factor = 1. The bioavailability was calculated as follows: Bioavailability (%) = l*^ 1 -"- ^° Se j x 100 (AUC i>v . / Dose) AUC (Area Under the Curve) was calculated by the SIPHAR program using the trapezoidal rule. Determination of nicotine in rat plasma Blood samples Blood samples (100 μl) were placed in centrifuge tubes added Heparin (3.4 μl, 3 U/ml). The tubes were centrifuged at 823 g for 15 min. The plasma supernatants were transferred to new tubes and kept at -22°C until analysis. Principle After precipitation of plasma proteins, nicotine in the organic supernatant was determined by capillary gas chromatography using a nitrogen phosporus detector. Determination of nicotine in the Spherex ® -microspheres The theoretical concentration of nicotine in the freeze-dried nicotine- Spherex ® formulation was 17 mg/100 mg Spherex ® microspheres. The actual concentration was determined by HPLC-analysis after 1 hour's extraction/degradation of the product in 0.025 M HCI. The actual content was by this method determined to be 14.2 mg nicotine base/100 mg Spherex ® particles. Intranasal administration of nicotine-Spherex ® -microspheres The nasal absorption of nicotine from the nicotine-Spherex ® microspheres was investigated in 10 rats. The mean nicotine concentrations in plasma as a function of time are shown in the below Table 1 and Figure 1. Table 1 Plasma nicotine values after intranasal administration of Spherex ® nicotine microspheres. The mean dose was 6.46 ± 0.58 mg Spherex/kg BW. Minutes after Average for 10 St. Dev nasal adm. rats 0 17 47,2 15 291 138,5 30 260 77,3 45 245 104,8 60 245 109,5 75 194 91 ,8 90 180 116,5 105 223 116,4 120 134 34,4 150 144 72,5 180 78 71 ,9 210 56 The data from all 10 experiments were used to calculate one set of pharmacokinetic parameters. This procedure was legal since the variation in drug dose was small (6.46 ± 0.58 mg Spherex ® particles/kg BW) and so was the variation in body weight (242 g ± 22 g). The intranasal administration of nicotine-Spherex ® microspheres resulted in a plasma peak value of 291 ng nicotine/ml plasma, which was obtained within 15 minutes after administration (t -- = 1.89 min). The pharmacokinetic parameters calculated by the SIPHAR-program are tabulated in the below Table 2 together with their standard deviation (SD). The elimination coefficient, K β , is fairly accurately determined but the absorption coefficient, K-., has a very large SD, probably due to too few data points representing the uptake phase. Table 2 Parameter Parameter S.D. C.V. (%) Half-life value (minutes) K. 0.3662 2.1858 596.9 1.89 K. 0.0056 0.0016 29.6 125 The AUC Q .. was calculated to a value of 56226 ng/ml x min. Intravenous administration of nicotine The plasma nicotine values as a function of time after i.v. administration of nicotine are shown in the below Table 3 and Figure 2. Six animals were used in the study. The pharmacokinetic parameters are calculated as described for the data obtained by intranasal administration. Table 3 Plasma nicotine values after intravenous administration of nicotine. The nicotine dose was 0.15 mg/kg BW. Minutes Average St Dev. after Lv. for 6 rats ad -, 15 47 36,1 30 61 23,9 45 86 78,1 60 50 43,1 75 51 32,2 90 38 50,0 105 38 38,3 120 59 55,4 150 36 36,0 180 22 52,0 210 25 19,1 240 20 33,5 The elimination coefficient, K β , is shown in the below Table 4. Table 4 Parameter Parameter S.D. C.V. (%) Half-life value (minutes) K. 0.0044 0.0022 49.93 156 An AUC „_.. has been calculated. The value was 15717 ng/ml x min. Bioavailability The bioavailability was calculated as: (AUC ± _ / Dose) Bioavailability (%) = ^^ DQse) x 100 The bioavailability was calculated to 58 % for the intranasal formulation. Further embodiments The powdery pharmaceutical composition according to the present invention might be administered not only via the nasal route, but possibly after modification within the scope of the invention, also orally, pulmonary or buccaily. Different additives, such as buffers, absorption enhancers, flavors and stabilizing agents, may be incorporated into the microspheres together with the nicotine in essentially the same way as the nicotine was incorporated according to the above Example 1. In the above Examples 1 and 2 was used nicotine in the form of nicotine base. Using essentially the same method as in Example 1 nicotine might instead be incorporated in the form of a salt or a molecular complex or combinations thereof including or not including also nicotine as a free base. In the above Examples 1 and 2 were used starch microspheres with an average diameter of 45 μm. Anyhow smaller as well as bigger particles might also be used without significant change in the bioavailability of the incorporated nicotine. A useful diameter range is from about 1 μm to about 200 μm. Particles within this diameter range are essentially deposited in the nasal cavity when administered nasally without being further transported to the lungs. Such particles are also to a great extent transported to the lungs when administered perorally. The particles used in the above Examples 1 and 2 contain about 14 mg nicotine base/100 mg starch microspheres. This concentration should anyhow not be regarded as the only possible or optimal concentration. Using different forms of nicotine it is possible to arrive at a very high concentration of nicotine in microspheres, up to 100 mg nicotine/100 mg unloaded starch microspheres, without thereby destroying the microspheres. The preferred concentration range, 12-40 mg nicotine/100 mg unloaded starch microspheres, is fairly wide due to the fact that when using microspheres with a high nicotine content a comparably small amount of microspheres is administered in order to arrive at the desired plasma concentration and vice versa.

Claims: CLAIMS 1. A powdery pharmaceutical composition comprising nicotine or a derivative thereof and starch microspheres. 2. A powdery pharmaceutical composition according to claim 1 , wherein starch microspheres are degradable epichlorhydrin cross-linked starch microspheres. 3. A powdery pharmaceutical composition according to claim 2, wherein the microspheres have a diameter between 0,1 and 200 μm. 4. A powdery pharmaceutical composition according to claim 3, wherein the average microsphere diameter is around 45 μm when swollen and more than 95 % of the microspheres have a diameter between 20 and 70 μm when swollen. 5. A powdery pharmaceutical composition according to anyone of the preceeding claims, characterized in that the nicotine is in the form of a free base or a salt or a molecular complex or combinations thereof. 6. A powdery pharmaceutical composition according to anyone of the preceeding claims, characterized in that the composition further comprises one or more additives being buffers, absorption enhancers, ■ flavors or stabilizing agents. 7. A powdery pharmaceutical composition according to anyone of the preceeding claims, characterized in that it is intended for nasal administration. 8. A powdery pharmaceutical composition according to anyone of the claims 1-6, characterized in that it is intended for oral administration. 9. A powdery pharmaceutical composition according to anyone of the claims 1-6, characterized in that it is intended for pulmonary administration. 10. A powdery pharmaceutical composition according to anyone of the claims 1-6, characterized in that it is intended for buccal administration. 11. A powdery pharmaceutical composition according to anyone of the preceding claims, characterized in that the nicotine concentration is from around 1 mg nicotine/100 mg unloaded starch microspheres to around 100 mg nicotine/100 mg unloaded starch microspheres, preferably from around 12 mg nicotine/100 mg unloaded starch microspheres to around 40 mg nicotine/100 mg unloaded starch microspheres. 12. A process for the manufacturing of a nicotine-containing powdery pharmaceutical composition wherein the following successive steps are carried out: - starch microspheres are mixed with nicotine solution in water, - the mixture is allowed to equilibrate, preferably between 0,1 and 24 hours, - the mixture is freeze dried and sieved to obtain a powdery formulation 13. A process according to claim 12, wherein starch microspheres are degradable epichlorhydrin cross-linked starch microspheres. 14. A method of diminishing the desire of a subject to smoke or sniff tobacco or chew tobacco, which comprises the step of administering to the subject a powdery pharmaceutical composition according to anyone of the claims 1 through 11.

Inventors: ALBRECHTSEN STEN, HANSEN JENS, MOELLGAARD BIRGITTE, ORUP-JACOBSEN LENE, ALBRECHTSEN, STEN, HANSEN, JENS, MOELLGAARD, BIRGITTE, ORUP-JACOBSEN, LENE
Applicants: ALBRECHTSEN STEN, HANSEN JENS, MOELLGAARD BIRGITTE, ORUP JACOBSEN LENE, PHARMACIA AB, ALBRECHTSEN, STEN, HANSEN, JENS, MOELLGAARD, BIRGITTE, ORUP-JACOBSEN, LENE
Application year: 1994
Main classification: A61K31
IPC codes: A61K9, A61K31, A61K47, A61P21